PURPOSE: Recently, it was reported that expression of transglutaminase 2 plays an important role in doxorubicin/cisplatin resistance in breast and ovarian cancer. The aims of this study were to verify the role of transglutaminase 2 in cisplatin response in non-small cell lung cancer (NSCLC) and to study if transglutaminase 2 gene (TGM2) methylation can be a molecular marker for good response to cisplatin. METHODS: TGM2 promoter methylation was analyzed by sodium bisulfite sequencing. Cisplatin sensitivity was analyzed by treatment of cisplatin in NSCLC cell lines with/without TGM2 or TGM2 siRNA transfection. RESULTS: In one-third of NSCLC cell lines, TGase 2 gene (TGM2) was silenced by promoter methylation. The TGM2 promoter-methylated cell lines (HCC-95 and HCC-1588) showed relatively higher sensitivity to cisplatin than the TGM2-expressing cell lines (NCI-H1299 and HCC-1195). Down-regulation and over-expression of TGM2 in those NSCLC cells also suggested a positive correlation of cisplatin sensitivity and TGM2 inhibition. With doxorubicin, the relationship was quite similar. CONCLUSIONS: We showed that good responders of cisplatin in NSCLC could be identified by the promoter methylation of TGM2 and that TGase 2 inhibition appears to be an effective cisplatin-sensitizing modality in NSCLC.
PURPOSE: Recently, it was reported that expression of transglutaminase 2 plays an important role in doxorubicin/cisplatin resistance in breast and ovarian cancer. The aims of this study were to verify the role of transglutaminase 2 in cisplatin response in non-small cell lung cancer (NSCLC) and to study if transglutaminase 2 gene (TGM2) methylation can be a molecular marker for good response to cisplatin. METHODS:TGM2 promoter methylation was analyzed by sodium bisulfite sequencing. Cisplatin sensitivity was analyzed by treatment of cisplatin in NSCLC cell lines with/without TGM2 or TGM2 siRNA transfection. RESULTS: In one-third of NSCLC cell lines, TGase 2 gene (TGM2) was silenced by promoter methylation. The TGM2 promoter-methylated cell lines (HCC-95 and HCC-1588) showed relatively higher sensitivity to cisplatin than the TGM2-expressing cell lines (NCI-H1299 and HCC-1195). Down-regulation and over-expression of TGM2 in those NSCLC cells also suggested a positive correlation of cisplatin sensitivity and TGM2 inhibition. With doxorubicin, the relationship was quite similar. CONCLUSIONS: We showed that good responders of cisplatin in NSCLC could be identified by the promoter methylation of TGM2 and that TGase 2 inhibition appears to be an effective cisplatin-sensitizing modality in NSCLC.
Authors: José Luis Ramirez; Rafael Rosell; Miquel Taron; Maria Sanchez-Ronco; Vicente Alberola; Ramon de Las Peñas; José Miguel Sanchez; Teresa Moran; Carlos Camps; Bartomeu Massuti; José Javier Sanchez; Fernanda Salazar; Silvia Catot Journal: J Clin Oncol Date: 2005-12-20 Impact factor: 44.544
Authors: Rafael Rosell; Manuel Cobo; Dolores Isla; Jose Miguel Sanchez; Miquel Taron; Giuseppe Altavilla; Mariacarmela Santarpia; Teresa Moran; Silvia Catot; Olatz Etxaniz Journal: Lung Cancer Date: 2005-12 Impact factor: 5.705
Authors: Paraskevi Briassouli; Florence Chan; Kay Savage; Jorge S Reis-Filho; Spiros Linardopoulos Journal: Cancer Res Date: 2007-02-15 Impact factor: 12.701
Authors: Lisa M Dyer; Kevin P Schooler; Lingbao Ai; Corinne Klop; Jingxin Qiu; Keith D Robertson; Kevin D Brown Journal: J Neurooncol Date: 2010-07-03 Impact factor: 4.130
Authors: Richard L Eckert; Mari T Kaartinen; Maria Nurminskaya; Alexey M Belkin; Gozde Colak; Gail V W Johnson; Kapil Mehta Journal: Physiol Rev Date: 2014-04 Impact factor: 37.312
Authors: Brian E Schwartz; Matthias D Hofer; Madeleine E Lemieux; Daniel E Bauer; Michael J Cameron; Nathan H West; Elin S Agoston; Nicolas Reynoird; Saadi Khochbin; Tan A Ince; Amanda Christie; Katherine A Janeway; Sara O Vargas; Antonio R Perez-Atayde; Jon C Aster; Stephen E Sallan; Andrew L Kung; James E Bradner; Christopher A French Journal: Cancer Res Date: 2011-03-29 Impact factor: 12.701
Authors: Frank Roossink; Steven de Jong; G Bea A Wisman; Ate G J van der Zee; Ed Schuuring Journal: Cell Oncol (Dordr) Date: 2012-07-27 Impact factor: 6.730